Last reviewed · How we verify
ATB-346 standard dose
ATB-346 is a nonsteroidal anti-inflammatory drug (NSAID) that selectively targets COX-2 to reduce gastrointestinal toxicity.
ATB-346 is a nonsteroidal anti-inflammatory drug (NSAID) that selectively targets COX-2 to reduce gastrointestinal toxicity. Used for Treatment of osteoarthritis.
At a glance
| Generic name | ATB-346 standard dose |
|---|---|
| Also known as | Active comparator |
| Sponsor | Antibe Therapeutics Inc. |
| Drug class | NSAID |
| Target | COX-2 |
| Modality | Small molecule |
| Therapeutic area | Pain |
| Phase | Phase 2 |
Mechanism of action
By selectively inhibiting COX-2, ATB-346 aims to minimize the gastrointestinal side effects associated with traditional NSAIDs, while maintaining analgesic and anti-inflammatory efficacy. This is achieved through a proprietary modification of the indomethacin scaffold, which enhances COX-2 selectivity.
Approved indications
- Treatment of osteoarthritis
Common side effects
- Gastrointestinal upset
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |